+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

“Biological Drug API Manufacturing market set to grow to $11bn by 2025” says Visiongain report

07 November 2019
Pharma

Visiongain has launched a new pharma report Biological Drug API Manufacturing Services World Industry and Market Forecast to 2029 : Mammalian Cell Cultures, Microbial Fermentations, and Other Expression Systems; Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines, and Others Therapeutic Areas.

The growth of the biosimilars market in the EU and the rise of generics will have a big effect on the biotech manufacturing services market. Consolidation as a strategy gives not only manufacturing capabilities, but access to cutting-edge technology and helps foster and establish relationships that can be used to enter new markets. Outsourcing as a strategy to reduce costs and increase efficiency can be a strength for biopharmaceutical companies. This trend in outsourcing will shift from the traditional model of using EU and US CMOs to outsourcing from lower emerging market CMOs, especially in Asia.

The lead analyst of the report commented "Strengths in the biotech contract manufacturing market, from the perspective of the CMOs, stem from the demand for lower cost manufacturing from companies of all sizes. This demand will continue to rise in the coming 10 years, Visiongain believes. CMOs can offer significant advantages in terms of cost and manufacturing flexibility for companies. Additionally, with many CMOs in the market, the range of services available to pharma companies is broad - CMOs have many opportunities to appeal to these pharma clients. CMOs can choose to specialise, providing a niche service or expertise in a particular formulation."

Leading companies featured in the report include Boehringer Ingelheim Abbvie, Boehringer Ingelheim BioXcellence, Catalent, Celltrion, Cytovance Biologics and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.

25 November 2022

Read

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.

25 November 2022

Read

Visiongain Publishes Dermatology CROs Market Report 2022-2032

The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.

23 November 2022

Read

Visiongain Publishes Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.

22 November 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever